Trial Profile
Phase III Study of AJM300 in Patients With Active Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Carotegrast (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Sponsors EA Pharma; Kissei Pharmaceutical
- 20 Jul 2023 Status changed from active, no longer recruiting to completed.
- 31 Mar 2022 Results presented in an EA Pharma Media Release.
- 31 Mar 2022 According to an EA Pharma media release, data published in The Lancet Gastroenterology & Hepatology.